Melflufen - a peptidase-potentiated alkylating agent in clinical trials-Reference-Cited by-同舟云学术

Melflufen - a peptidase-potentiated alkylating agent in clinical trials

Published:2017-06-08 Issue:39 Volume:8 Page:66641-66655
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Wickström Malin¹²,Nygren Peter¹³,Larsson Rolf¹,Harmenberg Johan⁴,Lindberg Jakob⁴,Sjöberg Per⁴,Jerling Markus⁴,Lehmann Fredrik⁵,Richardson Paul⁶,Anderson Kenneth⁶,Chauhan Dharminder⁶,Gullbo Joachim¹³

Affiliation:

1. Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University, Uppsala SE, Sweden

2. Department of Women’s and Children’s Health, Childhood Cancer Research Unit, Karolinska Institutet, Stockholm, Sweden

3. Department of Immunology, Genetics and Pathology, Uppsala University, SE-75185, Uppsala, Sweden

4. Oncopeptides AB, Västra Trädgårdsgatan 15, Stockholm, Sweden

5. Recipharm OT Chemistry AB, Sweden

6. Department of Medical Oncology, The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual-Action Therapeutics: DNA Alkylation and Antimicrobial Peptides for Cancer Therapy;Cancers;2024-09-10

2. The emerging role of melflufen and peptide-conjugates in multiple myeloma;Current Opinion in Oncology;2024-08-22

3. Targeted Drug Conjugates in Cancer Therapy: Challenges and Opportunities;Pharmaceutical Science Advances;2024-08

4. Small molecule anticancer drugs approved during 2021–2022: Synthesis and clinical applications;European Journal of Medicinal Chemistry;2024-06

5. PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-06